Letter to the Editor
Leukemia (2009) 23, 190–194; doi:10.1038/leu.2008.160; published online 3 July 2008
Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia
A Shimoni1, M Leiba1, M Schleuning2, G Martineau3, M Renaud3, M Koren-Michowitz1, E Ribakovski1, P le Coutre4, R Arnold4, F Guilhot3 and A Nagler1
- 1Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Aviv University, Tel-Hashomer, Israel
- 2Center for Bone Marrow Transplantation, Stiftung Deutsche Klinik für Diagnostik, Wiesbaden, Germany
- 3Department of Oncology, Hematology, Cell Therapy and CIC 802 INSERM, CHU La Miletrie, Poitiers, France
- 4Department of Hematology and Oncology,Charite-Universitatsmedizin, Berlin, Campus Virchow Klinikum Berlin, Germany
Correspondence: A Shimoni, E-mail: ashimoni@sheba.health.gov.il
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
Flying under the radar: the new wave of BCR?ABL inhibitors
Nature Reviews Drug Discovery Review (01 Oct 2007)
Imatinib and beyond?exploring the full potential of targeted therapy for CML
Nature Reviews Clinical Oncology Review (01 Sep 2009)
Nature Reviews Cancer Review (01 May 2007)
RESEARCH
Bone Marrow Transplantation Letter
Unrelated cord blood transplantation in CML: Japan Cord Blood Bank Network analysis
Bone Marrow Transplantation Original Article
